XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: Suitability as a biomarker for patient selection

被引:18
作者
Hatch, Stephanie B. [1 ]
Swift, Lonnie P. [2 ]
Caporali, Simona [3 ]
Carter, Rebecca [1 ]
Hill, Esme J. [1 ]
MacGregor, Thomas P. [1 ]
D'Atri, Stefania [3 ]
Middleton, Mark R. [1 ]
McHugh, Peter J. [2 ]
Sharma, Ricky A. [1 ]
机构
[1] Univ Oxford, Gray Inst Radiat Oncol & Biol, Canc Res UK Med Res Council, Oxford NIHR Biomed Res Ctr,Dept Oncol, Oxford OX3 7DQ, England
[2] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Dept Oncol, Oxford OX3 9DS, England
[3] Ist Dermopat Immacolata IRCCS, Mol Oncol Lab, I-00167 Rome, Italy
基金
英国医学研究理事会;
关键词
DNA repair; cytotoxic chemotherapy; tissue biomarker; cell cycle; NUCLEOTIDE EXCISION-REPAIR; IN-VITRO; DNA-REPAIR; CISPLATIN; LINES; BRAF; ENDONUCLEASE; DACARBAZINE; ERCC1-XPF; SURVIVAL;
D O I
10.1002/ijc.28454
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As the options for systemic treatment of malignant melanoma (MM) increase, the need to develop biomarkers to identify patients who might benefit from cytotoxic chemotherapy becomes more apparent. In preclinical models, oxaliplatin has activity in cisplatin-resistant cells. In this study, we have shown that oxaliplatin forms interstrand crosslinks (ICLs) in cellular DNA and that loss of the heterodimeric structure-specific endonuclease XPF-ERCC1 causes hypersensitivity to oxaliplatin in mammalian cells. XPF deficiency resulted in late S-phase arrest and persistence of double-strand breaks following oxaliplatin treatment. In a panel of 12 MM cell lines, oxaliplatin sensitivity correlated with XPF and ERCC1 protein levels. The knockdown of ERCC1 and XPF protein levels by RNA interference increased sensitivity of cancer cells to oxaliplatin; overexpression of exogenous ERCC1 significantly decreased drug sensitivity. Following immunohistochemical optimization, XPF protein levels were quantified in MM tissue samples from 183 patients, showing variation in expression and no correlation with prognosis. In 57 patients with MM treated with cisplatin or carboplatin, XPF protein levels did not predict the likelihood of clinical response. We propose that oxaliplatin should not be discarded as a potential treatment for MM on the basis of the limited activity of cisplatin in unselected patients. Moreover, we show that XPF-ERCC1 protein levels are a key determinant of the sensitivity of melanoma cells to oxaliplatin in vitro. Immunohistochemical detection of XPF appears suitable for development as a tissue biomarker for potentially selecting patients for oxaliplatin treatment in a prospective clinical trial. What's new? With options for systemic treatment of malignant melanoma (MM) on the rise, there is an increasing need to develop biomarkers for patient selection. To that end, this study explored the possibility of a biomarker to improve objective response rates to the drug oxaliplatin. The study reveals a mechanism by which mammalian cells are rendered hypersensitive to oxaliplatin that centers around the loss of endonuclease XPF-ERCC1. Sensitivity to oxaliplatin was directly related to XPF and ERCC1 protein levels. The findings indicate that XPF may be a suitable biomarker for MM patient selection for oxaliplatin therapy.
引用
收藏
页码:1495 / 1503
页数:9
相关论文
共 33 条
[1]   The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells [J].
Al-Minawi, Ali Z. ;
Saleh-Gohari, Nasrollah ;
Helleday, Thomas .
NUCLEIC ACIDS RESEARCH, 2008, 36 (01) :1-9
[2]   Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay [J].
Almeida, GM ;
Duarte, TL ;
Steward, WP ;
Jones, GDD .
DNA REPAIR, 2006, 5 (02) :219-225
[3]   Nucleotide excision repair genes as determinants of cellular sensitivity to cyclophosphamide analogs [J].
Andersson, BS ;
Sadeghi, T ;
Siciliano, MJ ;
Legerski, R ;
Murray, D .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 (05) :406-416
[4]   Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells [J].
Arora, Sanjeevani ;
Kothandapani, Anbarasi ;
Tillison, Kristin ;
Kalman-Maltese, Vivian ;
Patrick, Steve M. .
DNA REPAIR, 2010, 9 (07) :745-753
[5]  
Cancer Research UK, 2010, CANC STAT
[6]   Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases [J].
Carta, F ;
Demuro, PP ;
Zanini, C ;
Santona, A ;
Castiglia, D ;
D'Atri, S ;
Ascierto, PA ;
Napolitano, M ;
Cossu, A ;
Tadolini, B ;
Turrini, F ;
Manca, A ;
Sini, MC ;
Palmieri, G ;
Rozzo, C .
MELANOMA RESEARCH, 2005, 15 (04) :235-244
[7]   Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516
[8]   Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma [J].
Chapman, PB ;
Einhorn, LH ;
Meyers, ML ;
Saxman, S ;
Destro, AN ;
Panageas, KS ;
Begg, CB ;
Agarwala, SS ;
Schuchter, LM ;
Ernstoff, MS ;
Houghton, AN ;
Kirkwood, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2745-2751
[9]  
Curado M.P. E., 2007, Cancer Incidence in Five Continents, VIX
[10]   Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin [J].
De Silva, IU ;
McHugh, PJ ;
Clingen, PH ;
Hartley, JA .
NUCLEIC ACIDS RESEARCH, 2002, 30 (17) :3848-3856